-
1
-
-
0034680102
-
Molecular portraits of human breast tumours
-
COI: 1:CAS:528:DC%2BD3cXmt1CnsLw%3D, PID: 10963602
-
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
-
2
-
-
37049183697
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
COI: 1:CAS:528:DyaL2sXhtVSht7s%3D, PID: 3798106
-
Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
3
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
COI: 1:STN:280:DyaL1M3kt1Wntg%3D%3D, PID: 2470152
-
Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
4
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
COI: 1:CAS:528:DC%2BD2MXhtFansr3L, PID: 16236737
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
5
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
COI: 1:CAS:528:DC%2BD2MXhtFansr3F, PID: 16236738
-
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
6
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
COI: 1:CAS:528:DC%2BC3MXht12mtLvN, PID: 21991949
-
Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283
-
(2011)
N Engl J Med
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
-
8
-
-
84984900276
-
-
National Comphreensive Cancer Network (NCCN) guidelines, Breast Cancer, Version 2.2016 (2016) http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 27 July 2016
-
(2016)
Breast Cancer, Version
, vol.2
, pp. 2016
-
-
-
9
-
-
84905163505
-
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status
-
PID: 24777111
-
Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. doi:10.1093/jnci/dju055
-
(2014)
J Natl Cancer Inst
-
-
Howlader, N.1
Altekruse, S.F.2
Li, C.I.3
-
10
-
-
84873407216
-
Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
-
COI: 1:CAS:528:DC%2BC3sXitVOhs7o%3D, PID: 23011924
-
Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839–846
-
(2013)
Cancer
, vol.119
, pp. 839-846
-
-
Freedman, R.A.1
Hughes, M.E.2
Ottesen, R.A.3
-
11
-
-
84958240098
-
ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study
-
Byfield SD, Buck PO, Blauer-Peterson C et al (2016) ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. J Oncol Pract 12:159–160
-
(2016)
J Oncol Pract
, vol.12
, pp. 159-160
-
-
Byfield, S.D.1
Buck, P.O.2
Blauer-Peterson, C.3
-
12
-
-
84901692250
-
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
-
COI: 1:CAS:528:DC%2BC2cXntFOlt7k%3D, PID: 24756187
-
Freedman RA, Vaz-Luis I, Barry WT et al (2014) Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 145:491–501
-
(2014)
Breast Cancer Res Treat
, vol.145
, pp. 491-501
-
-
Freedman, R.A.1
Vaz-Luis, I.2
Barry, W.T.3
-
13
-
-
84899644277
-
Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study
-
COI: 1:CAS:528:DC%2BC2cXosVyisb8%3D, PID: 24516021
-
Vaz-Luis I, Keating NL, Lin NU et al (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927–934
-
(2014)
J Clin Oncol
, vol.32
, pp. 927-934
-
-
Vaz-Luis, I.1
Keating, N.L.2
Lin, N.U.3
-
14
-
-
84971664105
-
Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer
-
PID: 27069085
-
Reeder-Hayes K, Peacock Hinton S, Meng K et al (2016) Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 34:2003–2009
-
(2016)
J Clin Oncol
, vol.34
, pp. 2003-2009
-
-
Reeder-Hayes, K.1
Peacock Hinton, S.2
Meng, K.3
-
15
-
-
84905860749
-
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study
-
PID: 24888816
-
Vaz-Luis I, Ottesen RA, Hughes ME et al (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32:2142–2150
-
(2014)
J Clin Oncol
, vol.32
, pp. 2142-2150
-
-
Vaz-Luis, I.1
Ottesen, R.A.2
Hughes, M.E.3
-
16
-
-
17144465669
-
Measuring complications of cancer treatment using the SEER-Medicare data
-
Potosky AL, Warren JL, Riedel ER et al (2002) Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV62–IV68
-
(2002)
Med Care
, vol.40
, pp. IV62-IV68
-
-
Potosky, A.L.1
Warren, J.L.2
Riedel, E.R.3
-
17
-
-
0038478965
-
Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population
-
Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV3–IV18
-
(2002)
Med Care
, vol.40
, pp. IV3-IV18
-
-
Warren, J.L.1
Klabunde, C.N.2
Schrag, D.3
-
18
-
-
20044388527
-
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
-
COI: 1:CAS:528:DC%2BD2MXitVSnsLY%3D, PID: 15741529
-
Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073–1081
-
(2005)
JAMA
, vol.293
, pp. 1073-1081
-
-
Muss, H.B.1
Woolf, S.2
Berry, D.3
-
19
-
-
33745528525
-
Use and outcomes of adjuvant chemotherapy in older women with breast cancer
-
PID: 16782915
-
Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750–2756
-
(2006)
J Clin Oncol
, vol.24
, pp. 2750-2756
-
-
Giordano, S.H.1
Duan, Z.2
Kuo, Y.F.3
-
20
-
-
34447252614
-
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
-
PID: 17577029
-
Griggs JJ, Culakova E, Sorbero ME et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522–2527
-
(2007)
J Clin Oncol
, vol.25
, pp. 2522-2527
-
-
Griggs, J.J.1
Culakova, E.2
Sorbero, M.E.3
-
21
-
-
84869125207
-
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
-
COI: 1:CAS:528:DC%2BC3sXosVCltQ%3D%3D, PID: 22987084
-
Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792–3799
-
(2012)
J Clin Oncol
, vol.30
, pp. 3792-3799
-
-
Romond, E.H.1
Jeong, J.H.2
Rastogi, P.3
-
22
-
-
84905858933
-
Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01)
-
PID: 24912899
-
de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32:2159–2165
-
(2014)
J Clin Oncol
, vol.32
, pp. 2159-2165
-
-
de Azambuja, E.1
Procter, M.J.2
van Veldhuisen, D.J.3
-
23
-
-
84871319147
-
Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer
-
COI: 1:CAS:528:DC%2BC38XhvVCrsLfJ, PID: 23158536
-
Chen J, Long JB, Hurria A et al (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504–2512
-
(2012)
J Am Coll Cardiol
, vol.60
, pp. 2504-2512
-
-
Chen, J.1
Long, J.B.2
Hurria, A.3
-
24
-
-
84866060182
-
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study
-
COI: 1:CAS:528:DC%2BC38XhtlCqtr7N, PID: 22949432
-
Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293–1305
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 1293-1305
-
-
Bowles, E.J.1
Wellman, R.2
Feigelson, H.S.3
-
25
-
-
84892845082
-
Trastuzumab-related cardiotoxicity among older patients with breast cancer
-
COI: 1:CAS:528:DC%2BC3sXhvFOnu7jK, PID: 24127446
-
Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222–4228
-
(2013)
J Clin Oncol
, vol.31
, pp. 4222-4228
-
-
Chavez-MacGregor, M.1
Zhang, N.2
Buchholz, T.A.3
-
26
-
-
84984873301
-
Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: primary results of the MANTICORE randomized controlled trial. In: San Antonio breast cancer symposium
-
Pituskin EN, Mackey JR, Koshman S et al (2015) Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: primary results of the MANTICORE randomized controlled trial. In: San Antonio breast cancer symposium. San Antonio (abstr S1–05)
-
(2015)
San Antonio (abstr S1–05)
-
-
Pituskin, E.N.1
Mackey, J.R.2
Koshman, S.3
-
27
-
-
84984873309
-
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. In: 2015 American Heart Association Scientific Sessions
-
Gulati G, Heck SL, Hoffmann PS (2015) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. In: 2015 American Heart Association Scientific Sessions. Orlando (abstr 478895)
-
(2015)
Orlando (abstr 478895)
-
-
Gulati, G.1
Heck, S.L.2
Hoffmann, P.S.3
-
30
-
-
59949093293
-
Trends in racial and age disparities in definitive local therapy of early-stage breast cancer
-
PID: 19103731
-
Freedman RA, He Y, Winer EP, Keating NL (2009) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 27:713–719
-
(2009)
J Clin Oncol
, vol.27
, pp. 713-719
-
-
Freedman, R.A.1
He, Y.2
Winer, E.P.3
Keating, N.L.4
-
31
-
-
39049093871
-
Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?
-
PID: 18181101
-
Gross CP, Smith BD, Wolf E, Andersen M (2008) Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer 112:900–908
-
(2008)
Cancer
, vol.112
, pp. 900-908
-
-
Gross, C.P.1
Smith, B.D.2
Wolf, E.3
Andersen, M.4
-
32
-
-
33645455347
-
Missed opportunities: racial disparities in adjuvant breast cancer treatment
-
PID: 16549830
-
Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357–1362
-
(2006)
J Clin Oncol
, vol.24
, pp. 1357-1362
-
-
Bickell, N.A.1
Wang, J.J.2
Oluwole, S.3
-
33
-
-
84930149789
-
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
-
PID: 26022349
-
Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697–707
-
(2015)
Breast Cancer Res Treat
, vol.151
, pp. 697-707
-
-
Vaz-Luis, I.1
Lin, N.U.2
Keating, N.L.3
-
34
-
-
84876286032
-
Identifying specific chemotherapeutic agents in medicare data: a validation study
-
PID: 22080337
-
Lund JL, Sturmer T, Harlan LC et al (2013) Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care 51:e27–e34
-
(2013)
Med Care
, vol.51
, pp. e27-e34
-
-
Lund, J.L.1
Sturmer, T.2
Harlan, L.C.3
-
35
-
-
84920561845
-
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
-
PID: 25564897
-
Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134–141
-
(2015)
N Engl J Med
, vol.372
, pp. 134-141
-
-
Tolaney, S.M.1
Barry, W.T.2
Dang, C.T.3
-
36
-
-
0034531923
-
Development of a comorbidity index using physician claims data
-
COI: 1:STN:280:DC%2BD3M%2FptlSrtQ%3D%3D, PID: 11146273
-
Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258–1267
-
(2000)
J Clin Epidemiol
, vol.53
, pp. 1258-1267
-
-
Klabunde, C.N.1
Potosky, A.L.2
Legler, J.M.3
Warren, J.L.4
-
37
-
-
0027940266
-
Validation of a combined comorbidity index
-
COI: 1:STN:280:DyaK2M3jvFantQ%3D%3D, PID: 7722560
-
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251
-
(1994)
J Clin Epidemiol
, vol.47
, pp. 1245-1251
-
-
Charlson, M.1
Szatrowski, T.P.2
Peterson, J.3
Gold, J.4
|